- Home
- VFL vs CCCC Comparison
VFL vs CCCC Comparison
Compare VFL & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VFL
- CCCC
- Stock Information
- Founded
- VFL 1993
- CCCC 2015
- Country
- VFL United States
- CCCC United States
- Employees
- VFL N/A
- CCCC N/A
- Industry
- VFL Finance/Investors Services
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- VFL Finance
- CCCC Health Care
- Exchange
- VFL Nasdaq
- CCCC Nasdaq
- Market Cap
- VFL 118.0M
- CCCC 104.4M
- IPO Year
- VFL N/A
- CCCC 2020
- Fundamental
- Price
- VFL $9.47
- CCCC $2.26
- Analyst Decision
- VFL
- CCCC Buy
- Analyst Count
- VFL 0
- CCCC 3
- Target Price
- VFL N/A
- CCCC $12.00
- AVG Volume (30 Days)
- VFL 38.0K
- CCCC 2.0M
- Earning Date
- VFL 01-01-0001
- CCCC 08-04-2025
- Dividend Yield
- VFL 4.16%
- CCCC N/A
- EPS Growth
- VFL N/A
- CCCC N/A
- EPS
- VFL N/A
- CCCC N/A
- Revenue
- VFL N/A
- CCCC $39,783,000.00
- Revenue This Year
- VFL N/A
- CCCC N/A
- Revenue Next Year
- VFL N/A
- CCCC N/A
- P/E Ratio
- VFL N/A
- CCCC N/A
- Revenue Growth
- VFL N/A
- CCCC 98.56
- 52 Week Low
- VFL $7.93
- CCCC $1.09
- 52 Week High
- VFL $10.77
- CCCC $7.36
- Technical
- Relative Strength Index (RSI)
- VFL 37.90
- CCCC 60.73
- Support Level
- VFL $9.38
- CCCC $2.15
- Resistance Level
- VFL $9.60
- CCCC $2.53
- Average True Range (ATR)
- VFL 0.10
- CCCC 0.28
- MACD
- VFL -0.02
- CCCC 0.02
- Stochastic Oscillator
- VFL 25.00
- CCCC 62.13
About VFL abrdn National Municipal Income Fund
Delaware Investments Natl Muni Income is a closed-end investment fund. The Fund seeks to provide current income exempt from regular federal income tax consistent with the preservation of capital. The company's product portfolio includes Mutual funds, Exchange-traded funds, Private markets, Delaware Funds by Macquarie Premier Models, Managed accounts, Closed-end funds, and Variable Insurance Products.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.